NRX Pharmaceuticals, Inc. Interest Income, Other
NRX Pharmaceuticals, Inc. (NRXP) reported Interest Income, Other of $27.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-14.
Discontinued › Income Statement › Other Income
us-gaap:InterestIncomeOther · last filed 2024-05-14
- NRX Pharmaceuticals, Inc. interest income, other for the quarter ending 2024-03-31 was $27.00K, a 82.69% decline year-over-year.
- NRX Pharmaceuticals, Inc. interest income, other for the quarter ending 2023-12-31 was $74.00K, a 43.08% decline year-over-year.
- NRX Pharmaceuticals, Inc. interest income, other for the quarter ending 2023-09-30 was $119.00K, a 25.26% increase year-over-year.
- NRX Pharmaceuticals, Inc. interest income, other for the quarter ending 2023-06-30 was $145.00K, a 530.43% increase year-over-year.
- NRX Pharmaceuticals, Inc. interest income, other for fiscal 2023 was $494.00K, a 98.39% increase from fiscal 2022.
- NRX Pharmaceuticals, Inc. interest income, other for fiscal 2022 was $249.00K.
| Period end | Interest Income, Other 3 month | Interest Income, Other 6 month | Interest Income, Other 9 month | Interest Income, Other 12 month |
|---|---|---|---|---|
| 2024-03-31 | $27.00K 10-Q · filed 2024-05-14 | $101.00K derived: sum of 2 quarters · filed 2024-05-14 | $220.00K derived: sum of 3 quarters · filed 2024-05-14 | $365.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | $74.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $193.00K derived: sum of 2 quarters · filed 2024-03-29 | $338.00K derived: sum of 3 quarters · filed 2024-03-29 | $494.00K 10-K · filed 2024-03-29 |
| 2023-09-30 | $119.00K 10-Q · filed 2023-11-14 | $264.00K derived: sum of 2 quarters · filed 2023-11-14 | $420.00K 10-Q · filed 2023-11-14 | $550.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-06-30 | $145.00K 10-Q · filed 2023-08-14 | $301.00K 10-Q · filed 2023-08-14 | $431.00K derived: sum of 3 quarters · filed 2024-05-14 | $526.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-03-31 | $156.00K 10-Q · filed 2024-05-14 | $286.00K derived: sum of 2 quarters · filed 2024-05-14 | $381.00K derived: sum of 3 quarters · filed 2024-05-14 | $404.00K derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $130.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $225.00K derived: sum of 2 quarters · filed 2024-03-29 | $248.00K derived: sum of 3 quarters · filed 2024-03-29 | $249.00K 10-K · filed 2024-03-29 |
| 2022-09-30 | $95.00K 10-Q · filed 2023-11-14 | $118.00K derived: sum of 2 quarters · filed 2023-11-14 | $119.00K 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $23.00K 10-Q · filed 2023-08-14 | $23.00K 10-Q · filed 2023-08-14 | ||
| 2021-03-31 | $120.00K 10-Q · filed 2021-05-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |